Terns Pharmaceuticals (NASDAQ:TERN) is developing a portfolio of novel, oral small-molecule product candidates based on clinically validated mechanisms of action to address serious diseases including oncology and...
Terns Pharmaceuticals (NASDAQ:TERN) has announced the appointment of Andrew Gengos as chief financial officer (CFO), effective immediately. Mr. Gengos brings 25 years of leadership experience in life sciences and...